Browse by Poster Presenter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

A
Abdallah, Claude

Children's National Hospital
040: Assessment of Clinical Challenges With Application of Institute for Safe Medication Practices Targeted Medication Safety Best Practice: Injectable Promethazine
Claude Abdallah
Favorite
Abdelmageed, Mai

University of Florida
094: Analyzing First-in-Human Trial Designs of Antisense Oligonucleotides: A Preliminary Review Across Subcutaneous, Intravenous & Intrathecal Routes of Administration
Mai Abdelmageed
Favorite
Abdul Massih, Sandra

Johns Hopkins Univ School of Medicine
083: Pharmacokinetics of Tenofovir Alafenamide, Emtricitabine & Dolutegravir in a Patient on Peritoneal Dialysis
Sandra Abdul Massih
Favorite
Abduljalil, Khaled

Certara UK
085: Predicting Metoprolol Exposure-Response in Pregnant Population Using Physiologically-based Pharmacokinetic Modeling
Khaled Abduljalil
Favorite
Abouelhassan, Yasmeen

Merck & Co Inc
079: Exploring the Impact of Hepatic Impairment on the Pharmacokinetics of New Molecular Entities: A Comprehensive Analysis of Labeling Information
Yasmeen Abouelhassan
Favorite
Adebusuyi, Tolulope

US Food & Drug Administration
165: Demographic Composition of New Molecular Entities Approved by the United States FDA Between 2017 & 2023 to Treat Type 2 Diabetes
Tolulope Adebusuyi
Favorite
Ahn, Sara So Hyung

Genentech Inc
141: A Comparative Analysis of Pharmacokinetics of Oncology Drugs Between Healthy Volunteers & Patients With Cancer
Sara So Hyung Ahn
Favorite
Ait-Oudhia, Sihem

Merck & Co Inc
144: Population Pharmacokinetic Model for Tulisokibart in Healthy Participants
Sihem Ait-Oudhia
Favorite
Aktar, Hanifa

Shenandoah Univ
097: Comparison of Hypoxia Inducible Factor-1A Polymorphisms Between Chronic Kidney Disease Patients & Healthy Subjects
Hanifa Aktar
Favorite
Alikhani, Radin

University of Michigan, Ann Arbor
160: Modeling Age-related Changes in Kidney Function Using Aminoglycoside Clearance as a Surrogate: Can Body Composition Help?
Radin Alikhani
Favorite
Amajor, Victor

Children's Hospital of Philadelphia
A004: Cefepime Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children With Multiple Organ Dysfunction Syndrome
Victor Amajor
Favorite
A004: Cefepime Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children With Multiple Organ Dysfunction Syndrome
Victor Amajor
Favorite
Ameer, Barbara

Rutgers - Robert Wood Johnson Medical School
132: Strategic Selection of Clinical Trial Core Outcomes Customized to Disease & Drug Therapy: Examples Generated During coreVWD & coreHEM Initiatives
Barbara Ameer
Favorite
B
Bae, Jihyun

ORISE / US Food & Drug Administration
023: FDA & EMA Regulatory Recommendations on Fed Bioequivalence Study in Healthy Subjects vs Patients for Generic Drug Development
Jihyun Bae
Favorite
Barbour, April

8Clinical Pharmacology and Safety Sciences, Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca
124: A Drug-Drug Interaction Study to Evaluate the Impact of Coadministration of AZD0780 on Rosuvastatin Exposure in Healthy Participants
April Barbour
Favorite
C
Cao, Rui

University of Minnesota
142: Landscape Analysis of Dose Optimization Approaches in Oncology Investigational New Drug (IND) Submissions in 2023
Rui Cao
Favorite
Chamzas, Athanasios

University of Maryland, Baltimore
064: Pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian Healthy Adults & Adults With Uncomplicated Malaria
Athanasios Chamzas
Favorite
Chan, Cheuk Fung

Boehringer Ingelheim Intl GmbH
118: Evaluation of Drug-Drug Interaction in Nested Patient Studies
Cheuk Fung Chan
Favorite
Chang, Yuhua

US Food & Drug Administration
122: A Literature Review on the Performance of Tiny Tract for In Vitro Modeling to Predict Food-Drug & pH-Dependent Drug-Drug Interaction Risks
Yuhua Chang
Favorite
Chen, Li

University of North Carolina Eshelman School of Pharmacy and University of North Carolina Lineberger Comprehensive Cancer Center
043: Effects of the Innate Immune System, Body Habitus & Sex on the Pharmacokinetics & Antitumor Response of Anetumab Ravtansine in Patients With Solid Tumors
Li Chen
Favorite
Chen, Yingxue

Ipsen
030: Effects of Itraconazole & Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies
Yingxue Chen
Favorite
Chiang, Yi-Hua

Univ of Florida Coll of Pharmacy
088: Developing a Physiologically-based Pharmacokinetic Model Across Various Species Exploring Drug Interaction Potential of Mitragynine
Yi-Hua Chiang
Favorite
Choi, HeeJae

Boehringer Ingelheim Intl GmbH
036: Endogenous Biomarker Use in Renal Transporter-Mediated Drug Interactions: A Literature Review of Intrinsic, Extrinsic Factors & Disease Impact on Biomarker Levels
HeeJae Choi
Favorite
Chowdhury, Ekram Ahmed

AbbVie Inc
034: A Drug-Drug Interaction Study Between ABBV-903 & Midazolam in Healthy Participants
Ekram Ahmed Chowdhury
Favorite
Chu, Danny (Hoi Tsun)

Univ of California San Francisco School of Pharmacy
139: Imaging-based Anti-HIV Antibody Exposure in Anorectal Tissue Is More Closely Linked to Protective Efficacy During Clinical Prevention Trials
Danny (Hoi Tsun) Chu
Favorite
Conchon Costa, Ana Carolina

Univ of Florida Coll of Pharmacy
049: Assessment of the Effect of HBV Viral Genotype on Bepirovirsen Efficacy Using a Population Pharmacokinetic/Pharmacodynamic Modeling Approach
Ana Carolina Conchon Costa
Favorite
146: Optimizing Simvastatin Dosing in Patients Post-gastric Bypass Surgery Using a Population PK/PD Link Approach
Ana Carolina Conchon Costa
Favorite
D
Datta, Manu

PharmaPro Consulting
116: Addressing Disparities in Clinical Trial Participation: A Comparative Analysis of Cardiovascular & Oncology Studies
Manu Datta
Favorite
Denic, Kristina

Division of Research and Clinical Development, Travere Therapeutics, San Diego, California 92130, USA
032: The Effect of an Acid-reducing Agent, Esomeprazole on Sparsentan Pharmacokinetics in Healthy Volunteers
Kristina Denic
Favorite
114: Pharmacokinetic Characterization of Flotetuzumab in Pediatric Patients With Refractory/Relapsed Acute Myeloid Leukemia
Kristina Denic
Favorite
Desai, Devam

University of Florida
A009: A Translational Platform Quantitative Systems Pharmacology Model for Preclinical to Clinical Translation of In Vivo CRISPR-Cas9 Gene Therapy
Devam Desai
Favorite
A009: A Translational Platform Quantitative Systems Pharmacology Model for Preclinical to Clinical Translation of In Vivo CRISPR-Cas9 Gene Therapy
Devam Desai
Favorite
Dixit, Rakesh

King George's Medical university Lucknow, Uttar Pradesh, India, 226003
152: Pharmacoeconomic Analysis of Therapeutic Regimens Used for Treatment of Psoriasis in India
Rakesh Dixit
Favorite
Dodeja, Prerna

University of Pittsburgh School of Pharmacy
082: Mechanistic Physiologically-based Pharmacokinetic Modeling to Predict Bictegravir Drug Disposition in Pregnancy
Prerna Dodeja
Favorite
E
Enioutina, Elena

Division of Clinical Pharmacology, Pediatrics, School of Medicine, University of Utah
115: The Effectiveness of Anmarin, an Antimycotic Herbal Drug: Preclinical & Clinical Studies
Elena Enioutina
Favorite
F
Fandy, Tamer

Univ of Charleston
151: Genome-Wide CpG Methylation Profiling of Leukemia Cells Treated With Curcuminoids
Tamer Fandy
Favorite
Fang, Yunlan

Incyte Corporation
153: Population Pharmacokinetics/Pharmacodynamics Modeling of INCAGN02385 in Patients With Select Advanced Malignancies
Yunlan Fang
Favorite
Ford, Jennifer

Janssen Research & Development, LLC, a Johnson & Johnson Company
047: How Much PK Data Do We Really Need in Phase 3? A Milvexian Case Study
Jennifer Ford
Favorite
Franke, Ryan

Pfizer Inc
102: Sisunatovir Inhibition of Multiple Ion Channel Subtypes Prevents the Risk for QT Prolongation Due to hERG Channel Inhibition
Ryan Franke
Favorite
Frazier, Noah

Boehringer Ingelheim Intl GmbH
080: Is it Time to Retire Cockcroft-Gault & “Original” Schwarz Formulas in Drug Development?
Noah Frazier
Favorite
G
Garimella, Tushar

Daiichi Sankyo Inc
075: Population Pharmacokinetics of Trastuzumab Deruxtecan (T-DXd) in Subjects With HER2-mutant & HER2-overexpressing Non-Small Cell Lung Cancer (NSCLC)
Tushar Garimella
Favorite
138: Exposure-Response Analyses of Efficacy & Safety of Trastuzumab Deruxtecan to Inform Dosing Recommendation in HER2-mutant Non-Small Cell Lung Cancer
Tushar Garimella
Favorite
Gebhart, Anthony

University of Florida
A007: Dose Optimization of Cefazolin in Adult Cardiac Surgery With Cardiopulmonary Bypass After Albumin Supplementation
Anthony Gebhart
Favorite
A007: Dose Optimization of Cefazolin in Adult Cardiac Surgery With Cardiopulmonary Bypass After Albumin Supplementation
Anthony Gebhart
Favorite
German, Polina

Cytokinetics, Incorporated
022: Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants
Polina German
Favorite
Goh, Seoyoung

Seoul National University College of Medicine and Hospital
108: Pharmacokinetic Comparison of Ezetimibe/Rosuvastatin/Telmisartan Fixed-dose Combination vs Coadministration of Separate Treatments
Seoyoung Goh
Favorite
Gould, Errol

Enalare Therapeutics Inc.
105: ENA-001, a Novel BK-channel Blocker, Enhances Hypoxic Ventilatory Sensitivity and Alleviates Propofol-induced Respiratory Effects in Healthy Volunteers
Errol Gould
Favorite
148: The Mechanism of Action of an Innovative Respiratory Stimulant, ENA-001
Errol Gould
Favorite
Goyal, Navin

Janssen Research & Development, LLC, a Johnson & Johnson Co
052: Nipocalimab Pharmacokinetic/Pharmacodynamic & Exposure-Response Modeling in Pregnancies at Risk for Early-onset Severe (EOS) HDFN
Navin Goyal
Favorite
060: Pharmacokinetic Modeling of the IRF5 Antisense Oligonucleotide JNJ-66525433 & IRF5 mRNA Expression in Healthy Individuals
Navin Goyal
Favorite
Gupta, Vipul

Schrodinger Inc.
076: First-in-Human Phase 1 SAD, MAD, Food Effect & DDI Study of SGR-1505, a Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Inhibitor, in Healthy Volunteers
Vipul Gupta
Favorite
140: Pharmacokinetic-Pharmacodynamic Analysis of Cytokines in First-in-Human Phase 1 Dose Escalation Study of the MALT-1 Inhibitor, SGR-1505, in Healthy Volunteers
Vipul Gupta
Favorite
H
Haddish-Berhane, Nahor

Janssen Research & Development LLC
024: The Drug-Drug Interaction Effect of Steady State Rifampin Exposure on Single Dose Pharmacokinetics of Lazertinib
Nahor Haddish-Berhane
Favorite
107: Pharmacokinetic & Immunogenicity Results from the China Cohort of the MAJESTEC-1 Study of Teclistamab for Relapsed/refractory Multiple Myeloma
Nahor Haddish-Berhane
Favorite
Hanley, Michael

Takeda Development Center Americas, Inc.
070: Population Pharmacokinetic & Exposure-Response Analyses for the Phase 3 PhALLCON Study of Ponatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Michael Hanley
Favorite
Hong, Soyeon

Department of Pharmacy, Seoul National University Bundang Hospital
130: Clinical Outcomes of Carfilzomib-based Chemotherapy by Relative Dose Intensity in Patients with Relapsed or Refractory Multiple Myeloma
Soyeon Hong
Favorite
Hooper, Levi

Univ of Michigan
163: GLP-1-Induced Delays in GI Motility & Their Effects on Co-Administered Drug Absorption: A PBPK Analysis
Levi Hooper
Favorite
Huntjens, Dymphy

Priothera SAS
033: Clinical Assessment of Mocravimod as a Victim of Drug-Drug Interactions via CYP3A Metabolism & Transporters
Dymphy Huntjens
Favorite
J
Jain, Manav

University of Utah
133: Effect of Probiotics on the Levels of Neuroendocrine Biomarkers – A Systematic Review & Meta-Analysis
Manav Jain
Favorite
Jeon, Jae Yoon

Janssen Research & Development LLC
063: Preclinical & Clinical Pharmacokinetics of JNJ-75220795, A siRNA Therapeutic Targeting PNPLA3, for Metabolic-associated Steatohepatitis
Jae Yoon Jeon
Favorite
Jhunjhunwala, Kunal

Sanofi
128: Food & Formulation Effect of a Novel Src Homology Region 2 Domain−containing Protein Tyrosine Phosphatase 2 (SHP2) Allosteric Inhibitor in Combination With Pembrolizumab
Kunal Jhunjhunwala
Favorite
Johnson, Jordon

Arcus Biosciences Inc.
053: Concentration-QTc Analysis of Quemliclustat in Combination With/Without Zimberelimab & nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Cancer
Jordon Johnson
Favorite
K
Kang, Lijuan

Janssen Research & Development LLC
021: Strategic & Quantitative Recommendations on Bioanalytical Cross-Validation Experiment Design from a Clinical Pharmacology Perspective
Lijuan Kang
Favorite
112: Pharmacokinetics & Safety of Teclistamab Administered in the Arm or Thigh of Patients With Relapsed/Refractory Multiple Myeloma in MajesTEC-1
Lijuan Kang
Favorite
Kayesh, Ruhul

Center for Drug Evaluation and Research, US Food and Drug Administration
137: Application of Lactation Physiologically-based Pharmacokinetic Modeling to Predict Exposure of Select Compounds
Ruhul Kayesh
Favorite
Khwarg, Juyoung

Seoul National University College of Medicine and Hospital
045: Population Pharmacokinetics of GB-5001, a Long-acting Intramuscular Injection of Donepezil, in Healthy Participants
Juyoung Khwarg
Favorite
Kiang, Tony

University of Alberta
121: Organic Anion Transporter 3 Mediated Interactions in a Renal Proximal Tubule Epithelial Cellular Model: Effects of Mycophenolate & Prednisolone
Tony Kiang
Favorite
Kim, Kyeongmin

The Ohio State University
A010: Model-Based Assessment of the Contribution of Fc Proteins & Serum Proteins to the Elevated Clearance of Monoclonal Antibodies
Kyeongmin Kim
Favorite
A010: Model-Based Assessment of the Contribution of Fc Proteins & Serum Proteins to the Elevated Clearance of Monoclonal Antibodies
Kyeongmin Kim
Favorite
Kuo, Hsiao-Chen Dina

PMV Pharmaceuticals
044: Effect of Food on the Pharmacokinetics & Safety Profile of p53 Reactivator Rezatapopt in Healthy Subjects & Patients With Solid Tumors Harboring a TP53 Y220C Mutation
Hsiao-Chen Dina Kuo
Favorite
L
Langevin, Brooke

university of Maryland school of pharmacy
147: Real-World Insights into Drug Dosing Patterns for Commonly Prescribed Drugs During Pregnancy
Brooke Langevin
Favorite
Lee, Dowon

Seoul National Univ Coll of Medicine & Hosp
109: Pharmacokinetic Comparison Between Fixed-dose Combination of Rosuvastatin/Ezetimibe 2.5/10 mg & the Coadministration of Individual Formulations in Healthy Subjects
Dowon Lee
Favorite
Lee, Yunghon

US Food & Drug Administration
095: A Survey of Pharmacodynamic Biomarkers Bioanalysis in 20 Biologics License Applications Approved for Enzyme Replacement Therapy Indications
Yunghon Lee
Favorite
Leggas, Markos

St. Jude Children's Res Hospital
050: Modeling Effects of Lymphodepletion Therapy on CAR T-cell & Cytokine Dynamics
Markos Leggas
Favorite
051: Pharmacokinetically-Guided Dosing of Fludarabine for Lymphodepletion in CAR T-cell Therapy: A Clinical Trial Simulation Study
Markos Leggas
Favorite
Liang, Yali

Jazz Pharmaceuticals
158: Model-Informed Development of Recombinant Erwinia Asparaginase (JZP458) in Patients With Acute Lymphoblastic Leukemia
Yali Liang
Favorite
Lutz, Justin

Cytokinetics, Incorporated
074: A First-in-Human, Single & Multiple Ascending Dose Study of CK-4021586, A Novel Cardiac Myosin Inhibitor
Justin Lutz
Favorite
M
Madia, Priyanka
061: First-in-Human Evaluation of Pharmacokinetics & Safety of Tilpisertib Fosmecarbil, an Oral Prodrug of a Tumor Progression Locus 2 Inhibitor, in Healthy Volunteers
Priyanka Madia
Favorite
Mansbach, Oliver

89bio
031: No Increase in the Risk of Liver or Muscle Toxicity in Pegozafermin-treated Patients With Metabolic Dysfunction-Associated Steatohepatitis on Statin Background Therapy
Oliver Mansbach
Favorite
Masters, Joanna

Pfizer Inc
041: Population Modeling Framework With Adaptive Dosing for Optimizing Clinical Utility of Compounds in Development for Treatment of Solid Tumors
Joanna Masters
Favorite
Mathis, Cheryl

University of Utah
035: Potential Epigenetic Opioid-Chemotherapy Drug Interactions
Cheryl Mathis
Favorite
167: Acetaminophen Prescribing & Pharmacokinetic Analysis in Children, Adolescents & Young Adults With Cancer
Cheryl Mathis
Favorite
Max, Blake

University of Illinois at Chicago College of Pharmacy
020: Integration of the National HIV Curriculum at Accredited Graduate Programs of Pharmacy
Blake Max
Favorite
Miah, Kowser

AstraZeneca plc
026: Phase I Open Label Study to Evaluate the Effects of Savolitinib on the Pharmacokinetics of P-gp, OATP1B1/3, OCT2, MATE1/2K & OAT1/3 Substrates in Healthy Volunteers
Kowser Miah
Favorite
127: Phase I Open Label Study to Evaluate the Effects of Strong CYP1A2 Inhibitor on Savolitinib Pharmacokinetics in Healthy Volunteers
Kowser Miah
Favorite
Michael, Henry

McGill University
131: Network Analysis of Sedative Medication Use in a Canadian Cohort of People Living with HIV: Uncovering Potential Sedative Medication Drivers of Frailty States
Henry Michael
Favorite
Modi, Nishit

Protagonist Therapeutics, Inc
078: Pharmacokinetics, Pharmacodynamics & Safety of Rusfertide, A Hepcidin Mimetic, in Subjects With Hepatic Impairment & in Subjects With Renal Impairment
Nishit Modi
Favorite
Mo, Kyoung Hoon

Yonsei university
120: Effect of Herbal Medicines on the Pharmacokinetics of Donepezil
Kyoung Hoon Mo
Favorite
Monfared, Amelia

Chapman University
014: Analyzing the Association Between Single Nucleotide Polymorphisms & Combinations of Buprenorphine & Associated Metabolite Concentrations
Amelia Monfared
Favorite
N
Naderer, Odin

Chimerix, Inc.
054: The Effect of Moderate Hepatic Impairment on ONC201 (Dordaviprone) Pharmacokinetics
Odin Naderer
Favorite
143: The Effect of Severe Renal Impairment on ONC201 (Dordaviprone) Pharmacokinetics
Odin Naderer
Favorite
Nanah, Abdulaziz

Cytel
055: First-in-Human Population PKPD Modelling & Simulation of CUE-101: Preliminary Results
Abdulaziz Nanah
Favorite
Nanavati, Charvi

Pfizer Inc
071: Evaluation of Palbociclib & Combinatorial Chemotherapy Pharmacokinetics in Pediatric Patients With Recurrent or Refractory Solid Tumors
Charvi Nanavati
Favorite
Nguyen, May

Rutgers The State Univ of New Jersey
039: Incidence & Predictors of Stroke Mimic Amongst Patients Treated With Recombinant Tissue Plasminogen Activator: A Retrospective Comparison
May Nguyen
Favorite
Nguyen, Phuong

HaiPhong Univ of Medicine & Pharmacy
A003: Enhanced HLA-B*15:02 Screening Before Carbamazepine Therapy in Vietnam: Advancements in Real-Time PCR TaqMan Probe Procedure
Phuong Nguyen
Favorite
Nwabufo, Chukwunonso

University of Toronto
089: The Impact of COVID-19 Mediated Bidirectional Dysregulation of CYP3A4 on Systemic & Pulmonary Candidate Drug Concentrations
Chukwunonso Nwabufo
Favorite
O
Ousey, James

Arrowhead Pharmaceuticals
135: Population Kinetic-Pharmacodynamic Modeling of Multiple Lipid Biomarker Responses to Zodasiran in Patients With Mixed Dyslipidemia
James Ousey
Favorite
P
Paglialunga, Sabina

Celerion
025: No Clinically Meaningful Drug Interaction Between Futibatinib & Digoxin, Rosuvastatin or Quinidine
Sabina Paglialunga
Favorite
Park, Sang-In

Kangwon National University
129: Identification of Factors Associated With Vancomycin-Induced Acute Kidney Injury: An Analysis Using a Common Data Model
Sang-In Park
Favorite
Patel, Gina

Patel Kwan Consultancy
013: Use of Artificial Intelligence in Drug Development
Gina Patel
Favorite
Prokopienko, Alexander

Takeda Development Center Americas Inc., Cambridge, MA, USA
111: Effect of Food on the Pharmacokinetics, Safety & Tolerability of Budesonide Oral Suspension in Healthy Adults: A Randomized Phase 1 Study
Alexander Prokopienko
Favorite
R
Rahman, Mohammad Asikur

Binghamton Univ School of Pharmacy & Pharmaceutical Sciences
A006: Microfluidic Blood-Milk Barrier & Physiologically-based Pharmacokinetic Model to Predict Lofexidine Secretion into Breast Milk
Mohammad Asikur Rahman
Favorite
A006: Microfluidic Blood-Milk Barrier & Physiologically-based Pharmacokinetic Model to Predict Lofexidine Secretion into Breast Milk
Mohammad Asikur Rahman
Favorite
Ramsey, Laura

Children's Mercy Hosp & Clinics
098: CYP2B6 & CYP2C19 Phenotypes Influence Sertraline Exposure in Children & Adolescents
Laura Ramsey
Favorite
Riggs, Matthew

Metrum Research Group LLC
056: Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-targeted Loncastuximab Tesirine With Epcoritamab in B-cell Lymphoma
Matthew Riggs
Favorite
057: Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab & Glofitamab Guides Dosing in B-cell Lymphoma
Matthew Riggs
Favorite
Roychowdhury, Priyanka

Biogen-prod
119: Quantitative Assessment of Drug-Drug Interaction (DDI) Potential of BIIB122 on Oral Contraceptives Using a Physiologically-based Ppharmacokinetic Model
Priyanka Roychowdhury
Favorite
Rozakis, Rachel

Allucent
110: Phase 1, Single-Center, Randomized, Placebo-Controlled, Partially Blinded, Single Ascending Dose Study on the Effects of Troriluzole on corrected QT in Healthy Subjects
Rachel Rozakis
Favorite
S
Sahasrabudhe, Siddhee

Pfizer Inc
101: The SARS-CoV-2 Mpro Inhibitor Ibuzatrelvir is a Substrate but not an Inducer nor Inhibitor of CYP3A
Siddhee Sahasrabudhe
Favorite
Schmitz, Natalie

Biogen Inc
048: Population Pharmacokinetic and Exposure-response Analyses of anti-BDCA2 Antibody Litifilimab Support Its Clinical Benefit for Cutaneous Lupus Erythematosus
Natalie Schmitz
Favorite
093: Trends in First-in-Human Trials of Intrathecal Antisense Oligonucleotide Therapies: Insights into Dose Selection, Dose Escalation & Early Clinical Development
Natalie Schmitz
Favorite
Serna Pascual, Miquel

King's College London
077: Advanced Waveform Analysis of ECG Signals to Characterise Cardiac Drug Safety Between Caucasian & Japanese Volunteers
Miquel Serna Pascual
Favorite
Shaik, Naveed

Pfizer Inc
027: A Quantitative Evaluation of the Relationship Between Hepatic Extraction Ratio & Change in Plasma Half-Life Following Modulation of CYP3A Activity
Naveed Shaik
Favorite
Shao, Jie

Janssen Research & Development LLC
166: Fetal & Neonatal Drug Exposure Following Nipocalimab Treatment in Pregnant Women at Risk of EOS-HDFN
Jie Shao
Favorite
Sharaby, Sherif

Novartis Pharmaceuticals Corp
162: Pharmacokinetics of DYP688 in Patients With Metastatic Uveal Melanoma & Other GNAQ/11 Mutant Melanomas
Sherif Sharaby
Favorite
Shen, Jinshan

Relay Therapeutics
028: Drug-Drug Interactions of Lirafugratinib
Jinshan Shen
Favorite
164: No Clinically Relevant Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Lirafugratinib
Jinshan Shen
Favorite
Shenkoya, Babajide

University of Maryland Baltimore
090: Pharmacokinetics of Tetrahydrocannabinol in Infants Exposed to Breastmilk from Recreational Cannabis Users
Babajide Shenkoya
Favorite
Shin, Euibeom

Univ in Buffalo School of Pharmacy & Pharmaceutical Science
011: Evaluation of Prompt Engineering Strategies for Pharmacokinetic Data Analysis With the ChatGPT Large Language Model
Euibeom Shin
Favorite
Smith, Dakota

Vanderbilt Univ Medical Ctr
017: Pharmacist Administered Parenteral Medications: A Descriptive Study of a Novel Inpatient Training Program
Dakota Smith
Favorite
Sriwijaya, Jason

University of Minnesota
084: Exploration of Estimated Renal Function & Gabapentin Clearance in Older Adults
Jason Sriwijaya
Favorite
Steinbronn, Claire

Merck & Co Inc
117: Analyzing Drug-Drug Interaction Risk Assessment Strategies for Protein Therapeutics in Inflammatory Bowel Disease: A Literature-Based Evidence Review
Claire Steinbronn
Favorite
Stevenson, Matthew

Imperial Brands
161: Comparison of Nicotine Pharmacokinetic & Subjective Profiles of Three Modern Oral Nicotine Products & a Snus Product
Matthew Stevenson
Favorite
Sunkaraneni, Soujanya

Syndax Pharmaceuticals, Inc.
157: Pharmacokinetics & Exposure-Response Analyses of Revumenib Support Dosing in a Broad Population of Patients With Relapsed/Refractory Acute Leukemias
Soujanya Sunkaraneni
Favorite
Sun, Steven

UCSD
069: Population Pharmacokinetics of Bictegravir in Pregnant & Postpartum Persons Living With HIV
Steven Sun
Favorite
Suram, Anitha

Blueprint Medicines Corporation
A008: Using Clinical Data & Physiologically-based Pharmacokinetic Modelling to Assess the Effect of Hepatic Impairment on Avapritinib Pharmacokinetics to Guide Dose Adjustment
Anitha Suram
Favorite
A008: Using Clinical Data & Physiologically-based Pharmacokinetic Modelling to Assess the Effect of Hepatic Impairment on Avapritinib Pharmacokinetics to Guide Dose Adjustment
Anitha Suram
Favorite
T
Tarozzo, Maria Martha

School of Pharmaceutical Sciences of Ribeirao Preto - University of Sao Paulo
125: Pregabalin-codeine-disease Interactions in Patients With Acute Herpetic or Postherpetic Neuralgia
Maria Martha Tarozzo
Favorite
Taur, Jan-Shiang

US Food & Drug Administration
015: Characterizing the Covariates & their Impacts on Statistical Evaluations of Clinical Pharmacology Studies in the 351(k) Biologic License Applications
Jan-Shiang Taur
Favorite
Thalluri, Bhargavi

University of Tennessee health science center
019: Clinical Pharmacology Insights into Dosing Strategies of Approved Antibody-Drug Conjugates
Bhargavi Thalluri
Favorite
100: Sex-Related Differences in the Pharmacokinetics of Therapeutic Proteins
Bhargavi Thalluri
Favorite
Tian, Xiaofan

Boehringer Ingelheim Pharmaceuticals Inc
062: Absolute Oral Bioavailability of Nerandomilast in Healthy Male Study Participants
Xiaofan Tian
Favorite
Tortorici, Michael

Mineralys Therapeutics, Inc.
038: Lorundrostat Concentration-QTc Results from the First-in-Human Study in Healthy Participants Demonstrate Lack of Relevant Effect & Replaces the Thorough QT Study
Michael Tortorici
Favorite
Tran, Brittany

Daiichi Sankyo, Inc.
042: Pharmacokinetics & Exposure-safety Analyses Across Tumor Types for Ifinatamab Deruxtecan (I-DXd) in the First-in-Human Study IDeate-Pantumor01 (DS7300-A-J101)
Brittany Tran
Favorite
092: Concentration-QTc Interim Analysis of I-DXd in Subjects With Advanced Solid Tumors from Study IDeate-Pantumor01 (DS7300-A-J101)
Brittany Tran
Favorite
Tran, Tony

ORISE / US Food & Drug Administration
A002: A Comparative Review of Study Population & Dose Recommendations for In Vivo Bioequivalence Studies With Pharmacokinetic Endpoints Between FDA & EMA Guidances
Tony Tran
Favorite
Tseng, Leo

89bio
136: Population Pharmacokinetics & Pharmacodynamics of Pegozafermin, a Novel GlycoPEGylated FGF21, in a Phase 2 Study in Severe Hypertriglyceridemia
Leo Tseng
Favorite
V
Vaidya, Tanaya

AbbVie Inc
159: Pharmacokinetics, Pharmacodynamics & Safety of Budigalimab, An Anti-PD-1 Monoclonal Antibody, in People Living With HIV-1
Tanaya Vaidya
Favorite
van Duijn, Esther

TNO
155: The Human Metabolism of Lufotrelvir, a Prodrug for the Treatment of SARS-COV2, Investigated By LC+AMS
Esther van Duijn
Favorite
van Rongen, Anne

Leiden Univ
A005: Implications of Being Born Small for Gestational Age on the Exposure of Vancomycin & Gentamicin In Neonates
Anne van Rongen
Favorite
A005: Implications of Being Born Small for Gestational Age on the Exposure of Vancomycin & Gentamicin In Neonates
Anne van Rongen
Favorite
Vashi, Vijay

SK Life Science Inc
066: Population Pharmacokinetic Analysis of Cenobamate
Vijay Vashi
Favorite
Vatsalya, Vatsalya

University of Louisville
150: The Gut-immune-liver Axis in Patients With Alcohol Use Disorder & Clinically Low Serum Zinc Levels
Vatsalya Vatsalya
Favorite
Vernillet, Laurent

BioCryst Pharmaceuticals, Inc.
106: First-in-Human Safety, Pharmacokinetics & Pharmacodynamics of the Oral Factor D Inhibitor BCX10013
Laurent Vernillet
Favorite
Vuppugalla, Ragini

Kyowa Kirin Co Ltd
087: Development of a Pharmacokinetic-Tumor Target Engagement Model Using Nonclinical Data to Inform Phase 1 Dosing Scheme for a Novel Bispecific CD40-EpCAM Antibody, KK2269
Ragini Vuppugalla
Favorite
W
Wang, Chao

Univ of California San Francisco
096: Cluster Analysis to Identify Biomarkers of Treatment Response Following Sirolimus Treatment for HIV Cure
Chao Wang
Favorite
Wang, Diane

Pfizer Inc
068: Pharmacokinetic Analyses & Population Pharmacokinetic Modeling of Maplirpacept in Patients With Newly Diagnosed Acute Myeloid Leukemia
Diane Wang
Favorite
Wang, Ting

Indiana Univ School of Medicine
091: Clinical Pharmacology of Bispecific T-cell Engagers: A Summary Based on FDA Approvals
Ting Wang
Favorite
Wanta, Renee

Fortrea
067: The Impact of Late-Runner Participants on PK Variability in Healthy Volunteer, Single-Ascending Dose Trials
Renee Wanta
Favorite
Watanabe, Akiko

Daiichi Sankyo Co Ltd
029: Physiologically-based Pharmacokinetic Modeling of a Novel HER3-Targeted Antibody-Drug Conjugate, Patritumab Deruxtecan to Assess Pharmacokinetic Drug-Drug Interaction
Akiko Watanabe
Favorite
Welsh, Patrick

AbbVie Inc
046: Exposure-Response Analysis to Inform QT Prolongation Potential for Cedirogant
Patrick Welsh
Favorite
Wen, Ya-Feng

Gilead Sciences Inc
154: Pharmacokinetics of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors
Ya-Feng Wen
Favorite
156: Comparable Pharmacokinetics of Sacituzumab Govitecan Between Patients With Metastatic Urothelial Cancer & Metastatic Triple-Negative Breast Cancer
Ya-Feng Wen
Favorite
Won, Heejae

Seoul National University College of Medicine and Hospital
A001: Comparison of the Pharmacokinetics/Pharmacodynamics of a Fixed-Dose Combination of Rabeprazole/Magnesium Oxide 20/350 mg to the Enteric-Coated Rabeprazole 20 mg
Heejae Won
Favorite
Wu, Jianmei

Janssen Research & Development LLC.
065: Clinical Pharmacological Characterization of Cilta-cel, a CAR-T Therapy Directed Against BCMA in Adult Patients With Multiple Myeloma in a Multicohort CARTITUDE-2 Study
Jianmei Wu
Favorite
Y
Yang, Xinning

US Food & Drug Administration
123: Assessment of Impact of CYP3A4 Inducers on Investigational Drugs Informed By Clinical Drug-Drug Interaction Data: A Survey of Drugs Approved By FDA
Xinning Yang
Favorite
Z
Zahir, Hamim

Biogen Inc
037: Effect of Omaveloxolone @ Its Metabolites on Corrected QT Interval in Health Subjects
Hamim Zahir
Favorite
126: Effect of a Moderate CYP3A4 Inducer on the Pharmacokinetics of Omaveloxolone in Healthy Subjects
Hamim Zahir
Favorite
Zaidi, Syed Saoud

Indiana Univeristy
016: Comparative Pharmacokinetics & Bioequivalence Study of Gatifloxacin 200mg Tablets
Syed Saoud Zaidi
Favorite
145: Physiologically-based Pharmacokinetic Models of Opioid in Pregnancy, Maternal-Fetal, Pediatrics & Breastfeeding Mothers: A Systematic Literature Review
Syed Saoud Zaidi
Favorite
Zannikos, Peter

Janssen Research & Development, LLC, a Johnson & Johnson Company
072: Pharmacokinetics & Pharmacodynamics of Milvexian After Administration Every 12 Hours in Healthy Subjects
Peter Zannikos
Favorite
149: Milvexian Does Not Prolong the QTc Interval: A Thorough QT Study in Healthy Subjects
Peter Zannikos
Favorite
Zhang, Yi

US Food & Drug Administration
081: Exclusion of Pediatric Patients With Renal Impairment in Clinical Trials for Antiviral Products
Yi Zhang
Favorite
Zhou, Di

Amgen Inc
073: Clinical Pharmacology of Bemarituzumab in Gastric & Gastroesophageal Junction Cancer Patients Supports the Interchangeability of Q2W & Q3W Dosing Regimens
Di Zhou
Favorite
Zhou, Jin

Gilead Sciences Inc
113: Pharmacokinetics, Safety & Tolerability of GS-1427, a Pro-drug of a Potent & Selective Small-Molecule α4β7 Integrin Inhibitor, in Healthy Volunteers
Jin Zhou
Favorite
Ziesenitz, Victoria

Dept Pediatric Cardiology - Centre for Child and Adolescent Health
059: Perioperative Antibiotic Prophylaxis in Paediatric Cardiac Surgery – is One Day Sufficient to Prevent Surgical Site Infections?
Victoria Ziesenitz
Favorite